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Abstract 
Background: Most primary and metastatic bone tumors demonstrate increased osteoclast activity and bone resorp‑
tion. Current treatment is based on a combination of surgery, radiotherapy and chemotherapy. Severe side effects are 
associated with chemotherapy due to use of high dosage and nonspecific uptake. Bisphosphonates have a strong 
affinity to Ca2+ ions and are widely used in the treatment of bone disorders.
Results: We have engineered a unique biodegradable bisphosphonate nanoparticle (NPs) bearing two functional 
surface groups: (1) primary amine groups for covalent attachment of a dye/drug (e.g. NIR dye Cy 7 or doxorubicin); (2) 
bisphosphonate groups for targeting and chelation to bone hydroxyapatite. In addition, these engineered NPs con‑
tain high polyethyleneglycol (PEG) concentration in order to increase their blood half life time. In vitro experiments 
on Saos‑2 human osteosarcoma cell line, demonstrated that at a tenth of the concentration, doxorubicin‑conjugated 
bisphosphonate NPs achieved a similar uptake to free doxorubicin. In vivo targeting experiments using the NIR fluo‑
rescence bisphosphonate NPs on both Soas‑2 human osteosarcoma xenograft mouse model and orthotopic bone 
metastases mCherry‑labeled 4T1 breast cancer mouse model confirmed specific targeting. In addition, therapeutic 
in vivo experiments using doxorubicin‑conjugated bisphosphonate NPs demonstrated a 40% greater inhibition of 
tumor growth in Saos‑2 human osteosarcoma xenograft mouse model when compared to free doxorubicin.
Conclusions: In this research we have shown the potential use of doxorubicin‑conjugated BP NPs for the targeting 
and treatment of primary and metastatic bone tumors. The targeted delivery of doxorubicin to the tumor significantly 
increased the efficacy of the anti‑cancer drug, thus enabling the effective use of a lower concentration of doxorubicin. 
Furthermore, the targeting ability of the BP NPs in an orthotopic xenograft mouse model reinforced our findings that 
these BP NPs have the potential to be used for the treatment of primary and metastatic bone cancer.
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Background
It is well known that certain tumors have a predilection 
to metastasize to specific organs, for example breast, 
prostate, and lung cancers frequently metastasize to bone 
[1–3]. Most primary and metastatic bone tumors demon-
strate increased osteoclast activity and bone resorption 
[4–6] which may lead to pathological fractures, hypercal-
cemia and pain [3].
Current treatment for both primary and metastatic 
bone tumors includes a combination of surgery, radio-
therapy and chemotherapy [7, 8]. Although chemo-
therapy has increased the survival rate, poor bone blood 
supply [9] and non-tissue specificity necessitate the 
administration of high dosages, which consequently lead 
to severe side effects [7].
Bisphosphonates (BPs) are widely used in the treat-
ment of bone resorption disorders such as osteoporosis 
[10], Paget disease [11] and primary and metastatic bone 
tumors [12]. BP is a stable chemical analog of pyroph-
osphate, in which the oxygen in the P–O–P bonds is 
replaced with a carbon (P–C–P) causing it to be enzy-
matically stable [11]. BP, like pyrophosphate, has a high 
affinity to the bone mineral hydroxyapatite, by generat-
ing either a bidentate or a tridentate chelation with the 
Ca2+ ion in the mineral [11, 13]. The BP chelation to 
bone is reversed in an acidic environment causing osteo-
clasts to internalize BP into membrane-bound vesicles 
during resorption causing a disruption in osteoclast 
activity [14, 15].
Over recent decades much research has been directed 
towards the development of nanoparticles (NPs) in the 
field of targeted drug delivery. Biodegradable NPs have 
great potential due to their sub-micron size, biocompati-
bility and enhanced permeability and retention effect [16, 
17]. NPs provide protection from premature degrada-
tion and interaction with the biological environment, and 
enhance absorption and intracellular penetration of the 
drug to targeted tissue. In addition they enable greater 
control of the pharmacokinetics and drug body distri-
bution [18]. There are several ways to utilize the NPs as 
a drug delivery system: either the NP itself is composed 
of the drug and attached to a targeting agent or the NP 
is composed of the targeting agent, and the therapeutic 
agents are encapsulated or covalently attached to its sur-
face. Covalent biodegradable linkage (e.g., ester or amide 
bonds) confers the ability to accurately control the con-
centration of the drug attached and a known dosage can 
therefore be delivered and released at the targeted site 
[16]. Another application for the use of NPs is in the field 
of photonics for diagnostic imaging [19, 20].
Several research groups have utilized near-infrared 
(NIR) fluorescent dyes attached to NPs for in vivo imag-
ing [19, 21]. NIR fluorescence (700–900 nm) exhibits low 
auto-fluorescence and higher penetration, compared to 
UV and visible light, due to lower light scattering by the 
biological tissue at this wavelength [22, 23].
In this research we have synthesized a biodegrad-
able polymeric NP composed of a novel BP monomer, 
MA-PEG-BP (methacrylate polyethylene glycol BP), to 
target primary and secondary bone cancer, a primary 
amine containing monomer APMA (3-Aminopropyl)
mathacrylamide) for the covalent attachment of a drug/
dye to the surface of the NP and a crosslinker monomer 
tetra ethylene glycol diacrylate (TTEGDA). The incorpo-
ration of the high concentration of PEG endows the BP 
NPs with a relatively long blood half-life (5 h). This has 
been shown in  vivo in a young mouse model using the 
NIR fluorescent Cy7-conjugated BP NPs [24]. In addi-
tion, we have demonstrated the bone targeting ability 
of the BP NPs [24] and the high toxicity of doxorubicin-
conjugated BP NPs at low concentrations against osteo-
sarcoma cells [25].
In this study, we have successfully illustrated the tar-
geting ability of the BP NPs towards bone tumors in two 
in vivo mouse models. The NPs showed high selectivity 
for both osteosarcoma and breast cancer bone metasta-
ses. The therapeutic activity of the doxorubicin-conju-
gated BP was initially established using cell cycle studies 
on Soas-2 cells which demonstrated a greater uptake of 
the conjugated doxorubicin compared to free doxoru-
bicin. In vivo studies using a Saos-2 subcutaneous tumor 
in Hsd:Athymic Nude-Foxn1nu mice confirmed the 
enhanced bone tumor toxicity of the doxorubicin-conju-




The following analytical-grade chemicals were purchased 
from commercial sources and used without further puri-
fication: polyethylene glycol methacrylate (MA-PEG, Mn 
360), TTEGDA, polyethylene glycol methacrylate ether 
(MA-PEG-OCH3, Mn 300), potassium persulfate, O-[(N-
succinimidyl) succinyl-aminoethyl-O’-methylpolyeth-
ylene glycol (PEG-NHS, Mw 750), polyvinylpyrrolidone 
(PVP, Mw 360  K), sodium hydroxide (1  N), hydrochlo-
ric acid (1  N), anhydrous dichloromethane, anhydrous 
N,N-dimethylformamide, chromium oxide, isopropanol, 
magnesium sulfate (97%), triethylamine (99%), meth-
anesulfonyl chloride, sodium chloride, sodium azide 
(99.5%), Tris(trimethylsilyl)phosphite, glycine and O,O’-
bis[2-(N-succinimidyl-succinylamino)ethyl]polyethylene 
glycol (NHS-PEG-NHS,MW 3000) from Sigma (Rehovot, 
Israel); N-(3-aminopropyl) methacrylamide hydrochlo-
ride, (APMA) from Polysciences, Inc. (Warrington, PA); 
Dialysis membrane (1000  K-16MM), bicarbonate buffer 
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(BB, 0.1 M, pH 8.4), sodium carbonate and sodium bicar-
bonate from Bio-Lab Ltd. (Jerusalem, Israel); Cy 7-NHS 
ester from Lumiprobe Corporation (Florida, USA); doxo-
rubicin hydrochloride from Wonda science (Massachu-
setts, USA); Dulbecco’s phosphate-buffered saline (PBS), 
Dulbecco’s Minimum Essential Medium (DMEM), fetal 
bovine serum, glutamine, penicillin/streptomycin from 
Biological Industries (Bet Haemek, Israel); human oste-
osarcoma cell line Saos-2 and human colon carcinoma 
cell line SW620 from the American Type Culture Collec-
tion (Manassus, VA); Matrigel from Sigma (Germany); 
water was purified by passing deionized water through 
an Elgastat Spectrum reverse osmosis system (Elga Ltd., 
High Wycombe, UK).
Synthesis of the BP NPs
BP NPs were prepared similarly to that described in the 
literature [26]. Briefly, 45 mg MA-PEG-BP [27, 28], 5 mg 
APMA and 50  mg TTEGDA (5% w/v total monomer 
concentration) were added to a vial containing 8  mg of 
the initiator potassium persulfate (8% w/w) and 20  mg 
of the stabilizer polyvinylpyrrolidone 360  K (1% w/v) 
dissolved in 2 mL of bicarbonate buffer (0.1 M). For the 
polymerization, the vial containing the mixture was 
purged with N2 to exclude air and then shaken at 83  °C 
for 8 h. The obtained BP NPs were washed of excess rea-
gents by extensive dialysis cycles (cut-off of 1000 k) with 
purified water.
Synthesis of the NIR fluorescent BP NPs
NIR fluorescent BP NPs were synthesized similarly to 
that described in the literature [26]. In brief, NIR fluo-
rescent BP NPs were prepared by a reaction of the pri-
mary amino groups on the BP NPs with Cy7-NHS ester. 
Cy7-NHS ester (2 mg) was dissolved in 0.5 mL of anhy-
drous DMSO. 250 µL of the Cy7-NHS ester solution was 
then added to 5 mL of the BP NPs dispersion in 0.1 M 
bicarbonate buffer (2  mg/mL), and the reaction was 
stirred overnight at rt. Blocking of residual amine groups 
was then accomplished by adding 5 mg of O-[(N-succin-
imidyl) succinyl-aminoethyl-O’-methylpolyethylene gly-
col. The reaction was then stirred for 30 min at rt. The 
obtained NIR fluorescent-conjugated BP nanoparticles 
were then washed of excess reagents by extensive dialy-
sis in water.
NIR fluorescent control nanoparticles possessing 
OCH3 groups instead of the BP groups were prepared 
similarly, substituting the monomer MA-PEG-BP for 
MA-PEG-OCH3.
The fluorescence following the conjugation of Cy7 to 
both the BP and control NPs was verified by both UV and 
fluorescence and was found to be similar.
Synthesis of the doxorubicin‑conjugated BP NPs
Doxorubicin-conjugated BP NPs were synthesized simi-
larly to that described in the literature [25]. Doxorubicin-
conjugated BP NPs were prepared by an initial reaction of 
the primary amine group on the BP NPs with NHS-PEG-
NHS followed by the addition of doxorubicin. Briefly, 
NHS-PEG-NHS (10  mg) was dissolved in double dis-
tilled water (1 mL). 500 µL of the NHS-PEG-NHS solu-
tion was then added to 5  mL of the BP NPs dispersion 
in 0.1 M bicarbonate buffer (2 mg/mL), and the reaction 
was stirred at rt. After 10  min, 1  mg doxorubicin, ini-
tially dissolved in double distilled water, was added to the 
dispersion and was stirred for an additional 1  h. Block-
ing of residual amine groups was then accomplished by 
adding 50 mg of glycine to the doxorubicin BP NPs aque-
ous dispersion. The reaction was then stirred for a fur-
ther 30  min at rt. The obtained doxorubicin-conjugated 
BP NPs were then washed of excess reagents by extensive 
dialysis (cut-off of 1000 k) in water. The concentration of 
the conjugated doxorubicin was determined using fluo-
rescent intensity (λex 470 nm; λem 590 nm).
Cell cultures
Saos-2 osteosarcoma cell line cultures were grown in 
Dulbecco’s Minimum Essential Medium supplemented 
with 10% heat-inactivated fetal bovine serum, 1% glu-
tamine and 1% penicillin/streptomycin. 4T1 murine 
mammary adenocarcinoma cell line culture was grown in 
RPMI 1640 medium supplemented with 10% heat-inacti-
vated fetal bovine serum, 1% glutamine and 1% penicil-
lin/streptomycin. Cell lines were screened to ensure they 
remained mycoplasma-free using a myco-plasma detec-
tion kit.
mCherry‑infected 4T1 murine mammary adenocarcinoma 
cell line
Modified human embryonic kidney cell line GP2-293 
was co-transfected with pRetroQ-mCherry-N1 Vec-
tor using the complementary Retro-X™ Universal sys-
tem (Clontech, USA) to generate mCherry containing 
viral particles. 48 h following transfection, the pRetroQ-
mCherry-N1 retroviral particles containing supernatant 
were collected. 4T1 murine mammary adenocarcinoma 
cells (ATCC, USA) were infected with the retroviral par-
ticle media, and 48  h following the infection, mCherry 
positive cells were selected by Puromycin (2  µg/ml) 
resistance [29].
In vitro cell cycle studies
Cell cycle progression and apoptosis were analyzed 
by flow cytometry. For cell cycle analysis, Saos-2 cells 
(3 ×  105) were treated with doxorubicin-conjugated BP 
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NPs [500, 250, 125, 50, 25 and 10 ng(doxo)/ml], doxoru-
bicin and BP NPs (100 µg/ml) for 4 h. After incubation, 
cells were trypsinized, counted, and washed with culture 
medium. Cells were stained with Hoechst 33,342 solu-
tion according to the manufacturer’s protocol [30] and 
suspended in PBS. The cell suspension was analyzed by 
flow cytometry BD FACSAriaTM III (BD Biosciences, 
San Jose, CA, USA) with 488 and 405 nm lasers. A mini-
mum of 10,000 cells were analyzed for each histogram 
generated. Gate SSC/FSC was used to exclude fragments 
and aggregates from the cell count. For multicolor flow 
cytometry the cells were treated with (1) doxorubicin 
(analyzed using Cy5) and (2) Hoechst (DAPI cell cycle 
analysis). In both cases untreated cells were used as con-
trol. Results were analyzed using FlowJo software accord-
ing to the Dean–Jett–Fox model [31].
Animal experiments
All mice were weighed prior to and throughout the 
experiments (20–25 g). Experiments were conducted on 
a total of 100 8  week old Hsd:Athymic Nude-Foxn1nu 
female mouse model (Harlan Laboratories, Inc. Israel) 
and a total of 12 8 week old Balb/c female mice. Weight 
and tumor size were recorded weekly.
NIR fluorescent BP NPs targeting Saos‑2 subcutaneous tumor 
in Hsd:Athymic Nude‑Foxn1nu mice
In order to determine the bone tumor targeting abil-
ity of the NIR fluorescent BP NPs experiments with 
Hsd:Athymic Nude-Foxn1nu female mouse model (Har-
lan Laboratories, Inc. Israel) were carried out. Human 
osteosarcoma Saos-2 cells (3 ×  106) were suspended in 
100  µL matrigel mix (1:1) and injected subcutaneously 
into the nude mice (n  =  8). After a solid tumor was 
formed, three weeks post-subcutaneous injection, 100 µL 
Cy 7-conjugated BP NPs (0.1 mg/ml) suspended in PBS 
was IV injected via the tail vein. The mice were sacrificed 
at different time intervals and the tumors treated with 
NIR fluorescent BP and control NPs were studied by the 
Maestro II in  vivo imaging system, 2D planar fluores-
cence imaging of small animals (Cambridge Research & 
Instrumentation, Inc., Woburn, MA, USA). The experi-
ment was carried out twice.
The experiment was repeated with a subcutaneous 
tumor of SW620 human colon carcinoma cell line.
Saos‑2 subcutaneous tumor in Hsd:Athymic Nude‑Foxn1nu 
mice treated with doxorubicin‑conjugated BP NPs
In order to verify the doxorubicin-conjugated BP NPs 
anti-cancer activity, experiments on a Hsd:Athymic 
Nude-Foxn1nu female mouse model (Harlan Labora-
tories, Inc. Israel) were performed. The Dox-BP NPs 
were tested at two different concentrations: 1 and 2 mg/
ml with 5 and 10  µg (doxo)/ml (equivalent to 0.02 and 
0.04 mg/kg doxorubicin per injection), respectively. Con-
trol groups consisted of mice injected with free doxoru-
bicin 10 µg/ml (0.04 mg/kg) or BP NPs 2 mg/ml.
Human osteosarcoma Saos-2 cells (3 × 106) were sus-
pended in 100 µL matrigel mix (1:1) and injected subcu-
taneously into 8  week old female nude mice. The mice 
were randomly divided into 4 groups (n  =  8 repeated 
twice): 0.2 mg doxorubicin-conjugated BP NPs (1 µg dox-
orubicin), 0.1 mg doxorubicin-conjugated BP NPs (0.5 µg 
doxo), 1 µg doxorubicin and 0.2 mg BP–NPs. After one 
week, the mice were IV injected via the tail vein with 
100 µL of solution twice a week for 4 weeks. On the 30th 
day, mice were sacrificed using CO2 and tumors were 
extracted and weighed. The experiment was carried out 
twice using freshly synthesized NPs.
BP NPs ability to target mCherry‑labeled 4T1 breast cancer 
bone metastases in Balb/C mouse model
8 week old Balb/c female mice (Harlan Laboratories, Inc. 
Israel) were injected intra-tibia with 5 ×  105 mCherry-
labeled 4T1 cells suspended in matrigel [32]. One week 
post injection a tumor was present, and the mice were 
divided into two groups (n = 12). One group was treated 
with 100  µl of 0.1  mg/ml and the other group treated 
Cy7-conjugated BP nanoparticles or Cy7-conjugated con-
trol nanoparticles via IV injection into the tail vein. Mice 
were scanned after 72  h using Maestro in  vivo imaging 
system (Cy5 filter: λex 587 nm, λem 610 nm and Cy7 fil-
ter: λex 710–760 nm, λem > 750 nm; Cy5 exposure time 
0.5  s and Cy7 exposure 3  s), and then sacrificed. A Cy5 
filter was used to image the mCherry expressing tumor 
and a Cy7 filter for the NPs. Images were analyzed using 
ImageJ software. The experiment was carried out twice 
using freshly synthesized NPs.
Results
Synthesis of non‑fluorescent, NIR fluorescent 
and doxorubicin‑conjugated BP NPs
Functional crosslinked BP NPs of a dry diameter of 
43 ± 5 nm and a hydrodynamic diameter of 160 ± 13 nm 
were prepared as described in the experimental part, 
by heterogeneous dispersion co-polymerization of the 
new BP monomer MA-PEG-BP [27] with the mono-
mer APMA (3-Aminopropyl)mathacrylamide) and the 
crosslinker monomer TTEGDA (Fig. 1) [27]. These NPs 
were characterized using Dynamic light scattering and 
TEM and found to conform to those described in the 
literature [33]. The APMA monomer contains a primary 
amine group which allows for the covalent binding of a 
dye/drug to the surface of the particles as shown in Fig. 1. 
For optical imaging of bone tumor targeting we attached 
the NIR dye Cy7 to the surface of these particles [25, 33]. 
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For therapeutic purposes doxorubicin was bound to the 
surface of the BP NPs through a PEG spacer, as described 
in the literature, per 1  mg of BP NPs 5  µg doxorubicin 
was conjugated [25]. The synthesis of both the BP NPs 
and the conjugation of doxorubicin are incredibly repro-
ducible to that reported in the literature [25, 33]. Using 
the equation: V = g
d
= n · 4
3
· pi · r3 [d = density (1 g/ml); 
g = mass (1 g); r = radius (cm)], we were able to calculate 
the number (n) of BP NPs per mg (0.5 × 1012 particles), 
enabling us to determine the concentration of doxoru-
bicin per BP NP as 1 ×  10−14µg doxorubicin/NP. These 
NPs, due to their high content of BP, when administered 
by IV to chicken embryo model have been shown to spe-
cifically target bone tumor [25, 27, 33].
In vitro activity of doxorubicin‑conjugated BP NPs
The effect of doxorubicin-conjugated BP NPs on cell 
cycle was compared to free doxorubicin and studied 
using flow cytometry. Human Saos-2 cells were incu-
bated with free and conjugated doxorubicin at 10, 25, 50, 
125, 250 and 500 ng/ml for 24 h. Free doxorubicin dem-
onstrated no effect on cell cycle at the low dosages (10, 
25 and 50 ng/ml). At 250 ng/ml 26% of cells were in sub 
G1 phase and at 500  ng/ml 40% were in sub G1 phase, 
Fig. 2a. However, treatment with doxorubicin-conjugated 
BP NPs exhibited a dose-dependent increase in sub G1 
phase: 20% at 10 ng/ml, 31% at 25 ng/ml, 37% at 50 ng/
ml, 61% at 125  ng/ml, 82% at 250  ng/ml and 91% at 
500 ng/ml, Fig. 2b.
Fig. 1 Synthesis scheme of BP NPs and conjugation of either Cy 7 or doxorubicin (a). Size histogram (b) and TEM image (c) of BP NPs
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Using flow cytometry, cell uptake of free and conju-
gated doxorubicin was studied. Figure  3 exhibits the 
intracellular fluorescence of free doxorubicin (Fig.  3a) 
and conjugated doxorubicin (Fig.  3b) as a function of 
drug concentration. Cells treated with doxorubicin-
conjugated BP NPs exhibited a greater progressive shift 
in the fluorescence as a function of concentration. Fig-
ure  3c demonstrates the percentage of cells showing 
positive fluorescence due to doxorubicin as a function 
of concentration. At concentrations of 10, 25, 50, 125, 
250 and 500  ng/ml the measured fluorescent uptake of 
free doxorubicin was 1.2, 1.7, 6.5, 41.2, 83.7 and 97.8%, 
respectively, whereas for doxorubicin-conjugated BP NPs 
the measured fluorescent uptake was 20, 76.7, 96.4, 99.8, 
99.9 and 100%, respectively. Additional file  1: Figure S4 
demonstrates that there is no change in the morphology 
of Saos-2 cells following 4 h treatment with doxorubicin-
conjugated BP NPs (0.1 mg/ml).
NIR fluorescent BP NPs targeting human osteosarcoma 
Saos‑2 subcutaneous tumor in Hsd:Athymic Nude‑Foxn1nu 
mice
In order to evaluate the ability of the Cy7-conjugated BP 
NPs to target a bone tumor, human osteosarcoma Saos-2 
cells were injected subcutaneously into nude mice to 
induce an osteosarcoma xenograft. After a solid tumor 
was formed, Cy7-conjugated BP NPs and control NPs 
(0.1 mg/ml) were injected IV via the tail vein as described 
in the experimental part. The mice were sacrificed and 
the tumors were extracted after 1 and 7 days post-injec-
tion and analyzed using the Maestro II in  vivo imaging 
system. One day post injection, both NPs were clearly 
visible within the tumors, though the tumors treated with 
Cy 7-conjugated BP NPs exhibited a slightly higher fluo-
rescence (Fig.  4). 7  days post-injection the fluorescence 
of tumors treated with cy7-conjugated BP NPs was the 
Fig. 2 Cell cycle of Saos‑2 cell treated with doxorubicin (a) and 
doxorubicin‑conjugated BP NPs (b)
Fig. 3 Intracellular fluorescence of Soas‑2 cells treated with free doxorubicin (a) and doxorubicin‑conjugated BP NPs (b) as a function of drug 
concentration. Graph comparing positive cell uptake of free and conjugated doxorubicin as a function of drug concentration(c)
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same, whereas the fluorescence of the tumors treated 
with the cy7-conjugated control NPs decreased by 95%. 
The experiment was repeated using a tumor xenograft 
formed from SW620 human colon epithelial adenocarci-
noma cell line (data not shown). No preferential uptake 
of cy7-conjugated BP NPs in comparison to the control 
NPs was evident.
Therapeutic activity of doxorubicin‑conjugated BP NPs 
on human osteosarcoma Saos‑2 subcutaneous tumor in a 
nude mouse model
Anti-cancer activity of doxorubicin-conjugated BP NPs 
in a Saos-2 subcutaneous xenograft tumor in a nude 
mouse model was studied (Fig.  5). Doxorubicin-conju-
gated BP NPs 1 µg doxorubicin per injection (equivalent 
0.04 mg/kg doxorubicin per injection), free doxorubicin 
1 µg per injection (0.04 mg/kg doxorubicin per injection) 
and non-conjugated BP NPs (0.2 mg per injection) were 
IV injected via the tail vein twice a week for 30 days and 
the effect on tumor growth was compared.
After mice were sacrificed the tumor was extracted 
and weighed. The average tumor weight for conjugated 
doxorubicin at 1  µg per injection was 140  mg, for free 
doxorubicin at 1  µg per injection was 242  mg, and for 
non-conjugated BP NPs at 0.2  mg per injection it was 
230 mg, demonstrating a 40% difference between the free 
and conjugated doxorubicin (p < 0.05).
NIR fluorescent BP NPs targeting breast cancer bone 
metastases in an orthotopic mCherry‑labeled 4T1 tumor 
mouse model
Balb/c female mice were injected intra-tibia with 5 × 105 
mCherry-labeled 4T1 cells [32]. One week post injection 
the mice were treated with 100 µl of 0.1 mg/ml of either 
Cy7-conjugated BP nanoparticles or Cy7-conjugated con-
trol nanoparticles via IV injection into the tail vein. Mice 
were scanned after 72  h using Maestro in  vivo imaging 
system and images were analyzed using ImageJ software. 
The results obtained demonstrated that both NPs reach 
the tumor (Fig. 6). The Cy7-conjugated control NPs were 
present only at the periphery of the tumor. In contrast 
the Cy7-conjugated BP NPs were present throughout the 
whole tumor (Fig. 6a). Scans taken of the tumor, after the 
mice were sacrificed, showed that the fluorescence inten-
sity of Cy7-conjugated BP NPs was significantly (p < 0.01) 
higher than the control group (Fig. 6b).
Discussion
The results reported here demonstrate that the synthe-
sis of the poly(ethylene glycol) bisphosphonate NPs is 
repeatable and produces NPs of the same size and the 
same concentration of bound doxorubicin as previously 
reported. It should be noted that crosslinking of the NPs 
during the coupling of doxorubicin to the NPs via the 
coupling reagent NHS-PEG-NHS was not observed, as 
shown in Additional file  1: Figure S1, probably due to 
the chosen experimental conditions (diluted aqueous 
dispersion and excess concentration of the NHS-PEG-
NHS reagent as described in the experimental section). 
The high stability at physiological pH of the present NPs 
was confirmed by a negative zeta potential (−40 mV) as 
already demonstrated in our previous publications [25]. 
Furthermore, following the conjugation of doxorubicin 
to our novel poly(ethylene glycol) bisphosphonate NPs, 
a higher uptake and therapeutic effect was attained at 
lower concentrations than the free drug. Doxorubicin 
is known to affect the cell cycle [34, 35]. The cell cycle 
is divided into 3 main phases: G1 (growth and prepara-
tion for DNA division), S (duplication of DNA) and G2 
(pre-mitotic). Apoptotic cells exhibit fractional DNA 
content known as sub G1 phase. The effect of doxoru-
bicin-conjugated BP NPs on cell cycle was studied using 
flow cytometry to determine at what phase the treatment 
affects the cell. Human Saos-2 cells were incubated for 
24 h with various concentrations of free and conjugated 
doxorubicin (10, 25, 50, 125, 250 and 500 ng/ml). When 
compared with the control group (the untreated cells), 
cell cycle analysis of both the cells treated with the free 
doxorubicin (Fig.  2a) and the doxorubicin-conjugated 
BP NPs (Fig.  2b) showed an increase in the number of 
unviable cells in the sub G1 phase, as described in the 
Fig. 4 Targeting ability of Cy7‑cojugated BP NPs compared to control 
NPs. Histogram of the difference in fluorescence between day 1 and 
day 7 of each NP. The fluorescence of the BP NPs remains constant 
indicating that they are retained in the area of the tumor, whereas the 
fluorescence of the control NPs is reduced, indicating that they have 
been cleared from the tumor area (analyzed by ImageJ software). 
Error bars represent standard deviation
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literature [34, 35]. However, when comparing these two 
groups, the doxorubicin-conjugated BP NPs group exhib-
ited a greater number of cells in the sub G1 phase than 
the free doxorubicin group. At a low concentration of 
10  ng/ml doxorubicin, the doxorubicin-conjugated BP 
NPs exhibited 20% cell death, whereas cells treated with 
free doxorubicin showed a comparable cell death (25%) 
only at a concentration that was 25 times greater, 250 ng/
ml. In addition, at 500  ng/ml doxorubicin, 41% of the 
cells treated with free doxorubicin were in sub G1 phase, 
compared to 91% of cells treated with doxorubicin-conju-
gated BP NP. The increase in the number of unviable cells 
as a function of drug concentration could be explained by 
the greater intracellular concentration of doxorubicin, as 
indicated by the higher intracellular fluorescence of cells 
treated with doxorubicin-conjugated BP NPs (Fig.  3a) 
compared to the free doxorubicin (Fig. 3b), thus suggest-
ing a dose-dependent cellular uptake. Figure 3c exhibits 
the number of cells which have internalized doxorubicin. 
It is evident that when doxorubicin is conjugated to BP 
NPs, maximum cellular uptake is achieved at a tenth of 
the concentration, 96% at 50 ng/ml, compared to the free 
doxorubicin 97% at 500 ng/ml. Since the uptake of dox-
orubicin-conjugated BP NPs was much greater than the 
free doxorubicin, at a low concentration, the toxic effect 
of the conjugated doxorubicin was greater and the inter-
nal doxorubicin fluorescence increases with the increase 
in concentration. The shift in the fluorescence (Fig. 3) can 
be explained by the increase in intracellular fluorescence 
which is directly related to the increase in intracellular 
concentration of doxorubicin. These results support pre-
vious experimental findings in which Saos-2 cells that 
had been treated for 48  h with 250  ng/ml doxorubicin 
exhibited 58% viability, whereas cells treated with dox-
orubicin-conjugated BP NPs exhibited 10% viability. A 
similar picture was also seen using U-2OS cell line, where 
40 and 23% viability respectively was evident [25].
It has been reported in the literature that Saos-2 cells 
have osteoblastic properties and form a calcified matrix. 
In addition, it has been demonstrated that Saos-2 xeno-
grafts form an osteoid matrix, similar to woven bone, 
consistent with osteosarcoma [36–39]. The results 
obtained for the NIR fluorescent Cy 7-conjugated BP NPs 
targeting ability to Saos-2 subcutaneous tumor showed 
that 1  day post-injection (0.1  mg/ml), a higher fluores-
cence was seen compared to the control NPs (Fig.  4). 
Seven days post-injection revealed that the fluorescence 
of Cy 7-conjugated BP NPs remained constant within 
the tumor, whereas the fluorescence of the control NPs 
dramatically decreased by 95%. The tumor fluorescence 
could not be due to cleaved Cy 7, since Cy 7 is rapidly 
eliminated [40, 41]. The uptake of the Cy 7-conjugated 
BP NPs within the tumor and their retention over time 
can be explained by the high affinity of the BP functional 
group to Ca2+ ions, thereby endowing these BP NPs with 
the ability to preferentially target human osteosarcoma 
Saos-2 tumor. The initial uptake of the control NPs could 
be explained by the EPR effect, where increased vascu-
lar permeability leads to leakage of the blood-borne NPs 
into the tumor [42–45]. The specific uptake of BP NPs 
in osteosarcoma tumor was confirmed on repetition of 
the experiment, using a tumor xenograft formed from 
SW620 human colon epithelial adenocarcinoma cell line, 
where no preferential uptake was evident.
An earlier published study demonstrated the anti-
cancer activity of the doxorubicin-conjugated BP NPs 
in  vitro and in ovo, in a chicken embryo CAM tumor 
model [25]. In the current study we further investigated 
the anti-cancer activity of these doxorubicin-conjugated 
BP NPs in a Saos-2 subcutaneous xenograft tumor in a 
nude mouse model.
Results obtained demonstrate no change in tumor 
weight following treatment with the free doxorubicin 1 µg 
per injection (0.04  mg/kg), thereby indicating no toxic 
effect on the Saos-2 subcutaneous tumor growth. How-
ever, tumors treated with doxorubicin-conjugated BP 
NPs 0.5 µg doxorubicin per injection (0.02 mg/kg) exhib-
ited a 40% reduction in weight after 30  days’ biweekly 
injection (Fig.  5). It has been reported in the literature 
that the therapeutic effect of a series of IV injected doxo-
rubicin is achieved at 5 mg/kg [46]. In our study we were 
able to demonstrate a toxic effect of doxorubicin at a con-
centration 100 times lower. The enhanced toxic effect of 
Fig. 5 Effect on Saos‑2 subcutaneous xenograft tumor in nude 
mouse model following bi‑weekly IV injection for 30 days of 
doxorubicin‑conjugated BP NPs (1 µg doxorubicin per injection), free 
doxorubicin (1 µg per injection) and non‑conjugated BP NPs (0.2 mg 
per injection). *T test p < 0.05 and error bars represent standard devia‑
tion
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the doxorubicin when conjugated to BP NPs can only be 
explained by a higher concentration of doxorubicin deliv-
ered to the tumor by the specific targeting of the BP NPs. 
Hence, these results support the findings of the previous 
experiment and provide further evidence that the BP NPs 
specifically target osteosarcoma tumors, indicating the 
potential of doxorubicin-conjugated BP NPs for use as a 
drug delivery system in the treatment of osteosarcoma.
One major disadvantage of subcutaneous xenograft 
tumor models is that the microenvironment of the 
implanted tumor does not reproduce the environment 
in which the tumor grows [47–49]. However, it has been 
reported that a variety of tumor tissues when admin-
istered into the appropriate anatomical site in a mouse 
model, will often metastasize to similar locations as does 
the tumor in humans [32, 49, 50]. Therefore, after estab-
lishing the potential of the BP NPs targeting and thera-
peutic ability in a subcutaneous xenograft mouse model 
we continued our study in an orthotopic model. Breast 
cancer commonly metastasizes to bone [51–53] and we 
therefore orthotopically implanted mCherry-labeled 4T1 
mammary carcinoma cells intra-tibially in Balb/c mice 
[32] in order to produce bone tumor. Hence, this model 
provided an appropriate microenvironment for the eval-
uation of the tumor targeting ability of the BP NPs in 
bone.
Results obtained, following IV injection of Cy7-con-
jugated BP NPs and Cy7-conjugated control NPs (at the 
same initial fluorescence intensity), clearly indicated 
that both NPs reached the tumor area. The control NPs 
were seen to exhibit passive targeting which can be 
attributed to the EPR effect [43]. In contrast, the BP NPs 
demonstrated active tumor targeting as a result of the 
bone resorption, caused by the tumor invasion into the 
bone. Thus, we have shown that these BP NPs directly 
target bone tumors and have the potential to be utilized 
in the diagnosis and treatment of both primary and met-
astatic bone cancers.
Previous studies have shown that the combination 
of doxorubicin and nitrogen containing BPs lead to an 
improved therapeutic effect [54–56]. In this study how-
ever, the BPs in the engineered BP NPs did not contain 
nitrogen and showed no toxic effect on bone tumors and 
therefore were used only as a bone tumor targeting agent. 
We have not determined if a synergistic effect exists 
between the BP NPs combined with doxorubicin and fur-
ther research should be carried out.
There are several postulated mechanisms by which 
doxorubicin might cause cellular damage. At present the 
two most accepted theories are either intercalation of 
the doxorubicin into DNA, which leads to disruption of 
topoisomerase-II-mediated DNA repair and/or damage 
to cellular membranes by generation of free radicals [57]. 
However, the mechanism by which the surface bound 
doxorubicin NPs acts on cancer cells has not yet been 
determined. It is unclear whether the doxorubicin-con-
jugated NPs directly cause cellular damage or whether 
the cleavage of doxorubicin from the NPs is essential for 
cytotoxicity.
To summarize, we have shown the potential use of 
doxorubicin-conjugated BP NPs for the targeting and 
treatment of osteosarcoma. These doxorubicin-con-
jugated BP NPs, due to their high affinity to Ca2+ ions, 
enable the delivery of doxorubicin directly to the tumor. 
Fig. 6 Balb/c female mice were injected intra‑tibia with 4 × 105 mCherry‑labeled 4T1 cells. One week post injection the mice were treated with 
0.1 mg/ml of either Cy7‑conjugated BP nanoparticles or Cy7‑conjugated control nanoparticles. Fluorescent images (a) and histogram of extracted 
tumors (b) after 72 h post injection of Cy7‑conjugated BP nanoparticles. The marked area signifies the area of the tumor. Cy5 filter was used to 
image the mCherry expressing tumor along with Cy7 filter for the NPs
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We have confirmed that conjugation of doxorubicin to 
BP NPs significantly increases the anti-cancer activity of 
the drug against Soas-2 osteosarcoma cells, by increas-
ing the uptake of the anti-cancer drug in the cell com-
pared to the free drug. This was further investigated on 
human osteosarcoma Saos-2 subcutaneous tumor in a 
nude mouse model, where we verified the affinity of the 
doxorubicin-conjugated BP NPs to osteosarcoma tumors 
and their therapeutic activity on them. The results 
obtained have revealed that the targeted delivery of dox-
orubicin significantly increased the efficacy of the anti-
cancer drug, thus enabling the effective use of a lower 
concentration of doxorubicin. The targeting ability of the 
BP NPs in an orthotopic xenograft mouse model rein-
forced our findings that these BP NPs have the potential 
to be used for the treatment of primary and metastatic 
bone cancer.
The intention of this study was to assess the short term 
targeting and therapeutic potential of these novel BP 
NPs. We expect that since the NPs are highly hydrophilic 
and contain esteric bonds, the NPs are biodegradable. 
Our future plans include evaluating their biodegradabil-
ity. In addition, we intend to extend our investigation of 
the therapeutic activity of the doxorubicin-conjugated BP 
NPs in an in vivo osteosarcoma orthotopic model and in 
a genetically engineered mouse (GEM) model.
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